ProShare Advisors
SYRE icon

ProShare Advisors’s Spyre Therapeutics SYRE Stock Holding History

ProShare Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.12M Sell
12,599
-899
-7% -$65.6K ﹤0.01% 769
2026
Q1 		$681K Sell
13,498
-2,491
-16% -$93.9K ﹤0.01% 914
2025
Q4 		$524K Buy
15,989
+5,311
+50% +$139K ﹤0.01% 1109
2025
Q3 		$179K Sell
10,678
-1,801
-14% -$29.4K ﹤0.01% 1720
2025
Q2 		$187K Buy
12,479
+1,101
+10% +$16.3K ﹤0.01% 1740
2025
Q1 		$184K Sell
11,378
-1,153
-9% -$24K ﹤0.01% 1715
2024
Q4 		$292K Buy
+12,531
New +$367K ﹤0.01% 1654
2022
Q2 		– Sell
-507
Closed -$29K – 2102
2022
Q1 		$29K Sell
507
-124
-20% -$10.4K ﹤0.01% 2154
2021
Q4 		$75K Buy
631
+5
+0.8% +$789 ﹤0.01% 2238
2021
Q3 		$124K Sell
626
-146
-19% -$25.5K ﹤0.01% 1881
2021
Q2 		$134K Buy
772
+24
+3% +$4.36K ﹤0.01% 2239
2021
Q1 		$148K Buy
748
+52
+7% +$9.98K ﹤0.01% 2109
2020
Q4 		$137K Buy
696
+203
+41% +$42.1K ﹤0.01% 1939
2020
Q3 		$87K Sell
493
-20
-4% -$3.7K ﹤0.01% 1536
2020
Q2 		$119K Buy
+513
New +$97.7K ﹤0.01% 1550
2019
Q4 		– Sell
-432
Closed -$83K – 1801
2019
Q3 		$83K Buy
432
+14
+3% +$2.73K ﹤0.01% 1567
2019
Q2 		$72K Sell
418
-38
-8% -$6.57K ﹤0.01% 1558
2019
Q1 		$92K Buy
+456
New +$95.1K ﹤0.01% 1581

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

ProShare Advisors's SYRE Position: Q2 2026 in Review

ProShare Advisors reduced its Spyre Therapeutics (SYRE) stake by 6.7% in Q2 2026, selling an estimated $65.6K and leaving 12,599 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #769.

ProShare Advisors first reported a position in SYRE in Q1 2019 and has held it in 18 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • ProShare Advisors held 12,599 shares of Spyre Therapeutics worth $1.12M as of Q2 2026.
  • ProShare Advisors sold 899 Spyre Therapeutics shares in Q2 2026, an estimated $65.6K.
  • Spyre Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #769 holding.
  • ProShare Advisors first reported a position in Spyre Therapeutics in Q1 2019 and has held it in 18 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.